StockFacets
About
Sign-up
Sign-in
Earnings Calendar
Prices are updated after-hours
Published
Previous years
1708
This month
16
This week
4
This year
127
Today
2
Yesterday
3
Publishing Date
2023 - 06 - 27
6
2023 - 05 - 15
6
2023 - 05 - 09
6
2023 - 05 - 03
5
2023 - 04 - 27
7
2023 - 04 - 20
5
2023 - 02 - 22
5
2023 - 01 - 26
5
2023 - 01 - 09
6
2022 - 12 - 22
5
2022 - 11 - 07
5
2022 - 11 - 03
5
2022 - 08 - 08
7
2022 - 08 - 04
7
2022 - 07 - 28
5
2022 - 07 - 18
7
2022 - 06 - 28
5
2022 - 06 - 20
5
2022 - 06 - 14
5
2022 - 06 - 13
6
2022 - 06 - 07
6
2022 - 06 - 06
6
2022 - 05 - 11
7
2022 - 04 - 26
7
2022 - 04 - 11
7
2022 - 03 - 01
8
2022 - 02 - 24
6
2022 - 02 - 22
5
2021 - 12 - 13
5
2021 - 12 - 03
5
2021 - 11 - 04
6
2021 - 10 - 18
5
2021 - 10 - 13
5
2021 - 09 - 30
6
2021 - 09 - 28
7
2021 - 09 - 09
5
2021 - 09 - 07
5
2021 - 08 - 18
5
2021 - 08 - 16
6
2021 - 08 - 09
6
2021 - 08 - 03
8
2021 - 07 - 29
6
2021 - 07 - 14
5
2021 - 07 - 09
5
2021 - 06 - 29
6
2021 - 06 - 24
5
2021 - 06 - 22
5
2021 - 06 - 21
5
2021 - 06 - 17
5
2021 - 06 - 08
5
2021 - 06 - 07
6
2021 - 06 - 03
5
2021 - 06 - 01
6
2021 - 05 - 20
5
2021 - 05 - 11
5
2021 - 05 - 04
6
2021 - 04 - 20
7
2021 - 04 - 14
6
2021 - 04 - 13
8
2021 - 04 - 07
7
Sector
Commercial services
13
Communications
8
Consumer durables
1
Consumer non-durables
13
Consumer services
1
Distribution services
6
Electronic technology
13
Finance
21
Finance and insurance
1
Health services
28
Health technology
1708
Industrial services
1
Information
1
Manufacturing
81
N/a
18
Non-energy minerals
1
Process industries
13
Producer manufacturing
7
Professional, scientific, and technical services
22
Retail trade
2
Technology services
15
Transportation
1
Transportation and warehousing
1
Tags
Agreement
25
Alliances
39
Alzheimer's
23
Alzheimer’s
23
Antibody
51
Approval
46
Biomidwest
40
Biopharma
36
Biotech-bay
24
Biotechnology
25
Cancer
139
China
47
Chinese
28
Clinical-trials-phase-iii
32
Collaboration
71
Companies
51
Conference
76
Covid
62
Covid-19
48
Designation
22
Diabetes
57
Disease
89
Drug
105
Earnings
45
Events
32
Expected
24
Fda
71
Financial
65
Financial results
42
Global
149
Growth
108
Health
30
Heart
23
Insulin
37
Iot
23
License
26
Market
305
Meeting
26
Money
34
N/a
1119
Obesity
28
People
70
Pharma
35
Pharmaceutical
24
Phase 1
24
Phase 2
34
Phase 3
47
Positive
30
Report
140
Research
148
Results
203
Risk
24
Study
74
Technology
27
Therapeutics
138
Therapy
88
Tirzepatide
24
Treatment
175
Trial
116
Update
33
Entities
Abbott laboratories
56
Abbvie inc.
111
Abcellera biologics inc
12
Ac immune sa
35
Adc therapeutics sa
13
Agios pharmaceuticals, inc.
10
Akouos, inc.
11
Alnylam pharmaceuticals, inc.
38
Amgen inc.
88
Astellas pharma inc
25
Astrazeneca plc
97
Aveo pharmaceuticals, inc.
25
Baxter international inc.
14
Becton, dickinson and company
21
Beigene, ltd.
19
Biocryst pharmaceuticals, inc.
13
Biogen inc.
20
Biontech se
14
Blueprint medicines corporation
20
Boston scientific corporation
10
Bristol-myers squibb company
106
Clovis oncology, inc.
20
Eli lilly and company
1708
Epizyme, inc.
20
Exelixis, inc.
13
Gilead sciences, inc.
35
Glaxosmithkline plc
106
Hutchison china meditech limited
11
Icon plc
10
Illumina, inc.
15
Incyte corporation
207
Insulet corporation
14
Johnson & johnson
175
Karyopharm therapeutics inc.
20
Ligand pharmaceuticals incorporated
10
Medtronic plc
14
Merus n.v.
21
Nektar therapeutics
10
Novartis ag
138
Novo nordisk a/s
82
Omeros corporation
15
Otonomy, inc.
13
Pfizer, inc.
80
Point biopharma global inc
10
Precision biosciences, inc.
11
Proqr therapeutics n.v.
17
Regeneron pharmaceuticals, inc.
36
Rigel pharmaceuticals, inc.
41
Sanofi
335
Takeda pharmaceutical company limited
42
Terumo corp
14
Teva pharmaceutical industries ltd
61
Thermo fisher scientific inc
14
Ucb s.a.
11
United therapeutics corporation
14
Verastem, inc.
11
Vertex pharmaceuticals incorporated
12
Veru inc.
57
Viatris inc.
18
Y-mabs therapeutics, inc.
18
Symbols
AAPL
1193
ABB
1423
ABBV
1023
ABLZF
1162
ABT
1784
ACN
600
AMGN
742
ARVL
4285
AZN
664
BDX
796
BMY
662
BNPQF
1764
BNPQY
1764
CSCO
895
DHR
785
ERIC
1607
F
641
FNCTF
7171
FRBA
595
GE
915
GLAXF
657
GOOG
1274
GOOGL
1273
GSK
883
HON
1779
HUBS
1400
IBM
654
INTC
954
IT
590
JNJ
4571
LLY
1708
LTUM
970
LYV
717
MDT
1285
MMM
938
MS
4279
MSFT
1199
MT
588
NOC
588
NOK
898
NOKBF
972
NVO
631
NVS
1241
NVSEF
1031
ORCL
1157
PCRFF
650
PCRFY
650
PFE
692
PHG
962
PPRUF
1126
PPRUY
1127
SAP
1474
SAPGF
1228
SNOW
794
SNY
4532
SNYNF
3590
TEVJF
630
TMO
1621
VZ
1211
XYF
674
Exchanges
Amex
5
Nasdaq
1087
Nyse
1708
Crawled Date
2023 - 11 - 01
5
2023 - 10 - 04
5
2023 - 10 - 02
5
2023 - 07 - 25
5
2023 - 07 - 17
5
2023 - 06 - 27
6
2023 - 06 - 26
5
2023 - 05 - 15
6
2023 - 05 - 09
6
2023 - 05 - 03
5
2023 - 04 - 27
5
2023 - 04 - 20
5
2023 - 02 - 28
5
2023 - 01 - 26
5
2023 - 01 - 09
6
2022 - 12 - 22
5
2022 - 11 - 07
5
2022 - 08 - 08
7
2022 - 08 - 04
7
2022 - 07 - 28
5
2022 - 07 - 18
6
2022 - 06 - 20
5
2022 - 06 - 14
5
2022 - 06 - 13
6
2022 - 06 - 07
6
2022 - 06 - 06
7
2022 - 05 - 11
7
2022 - 04 - 26
7
2022 - 04 - 11
8
2022 - 03 - 01
8
2022 - 02 - 22
5
2021 - 12 - 13
5
2021 - 12 - 03
5
2021 - 11 - 04
5
2021 - 10 - 18
5
2021 - 10 - 13
5
2021 - 09 - 30
6
2021 - 09 - 28
7
2021 - 09 - 09
5
2021 - 09 - 07
5
2021 - 08 - 18
5
2021 - 08 - 16
6
2021 - 08 - 09
7
2021 - 08 - 03
8
2021 - 07 - 29
6
2021 - 07 - 14
5
2021 - 07 - 09
5
2021 - 06 - 29
6
2021 - 06 - 24
5
2021 - 06 - 22
6
2021 - 06 - 08
5
2021 - 06 - 07
6
2021 - 06 - 01
5
2021 - 05 - 20
5
2021 - 05 - 11
5
2021 - 05 - 04
6
2021 - 04 - 20
7
2021 - 04 - 14
6
2021 - 04 - 13
10
2021 - 04 - 07
7
Crawled Time
00:00
71
00:01
1
00:20
9
01:00
114
01:15
1
02:00
26
02:11
1
03:00
13
04:00
5
04:20
8
05:00
13
06:00
11
06:20
1
07:00
13
08:00
22
09:00
19
10:00
29
10:51
1
11:00
107
11:36
1
12:00
175
12:03
2
12:07
5
12:09
2
12:11
6
12:15
19
12:20
29
12:30
19
12:34
1
12:39
1
12:40
1
13:00
104
13:01
1
13:15
8
13:20
25
13:30
11
14:00
77
14:15
8
14:20
11
14:30
18
15:00
83
15:15
3
15:20
22
15:30
19
16:00
93
16:20
9
17:00
66
18:00
61
18:17
2
18:20
2
18:31
2
19:00
54
19:11
2
20:00
46
20:20
3
21:00
93
22:00
71
22:04
2
23:00
50
23:07
2
Source
brightmindsbio.com
1
investor.alkermes.com
2
investor.aveooncology.com
2
ir.cyclerion.com
1
ir.pulmatrix.com
1
ir.vaccinex.com
1
www.aspenpharma.com
2
www.biospace.com
589
www.brickellbio.com
2
www.chi-med.com
1
www.clarivate.com
1
www.concertpharma.com
1
www.cowen.com
1
www.emmis.com
1
www.fda.gov
37
www.firstbankonline.com
1
www.globenewswire.com
200
www.hutch-med.com
2
www.precisionbiosciences.com
2
www.preludetx.com
1
www.prnewswire.com
858
www.thermogenesis.com
1
Sort by:
after hours % change
|
delayed % change
|
gain open
|
gain high
|
gain close
|
publishing date
(GMT-12:00) International Date Line West
(GMT-11:00) American Samoa
(GMT-11:00) Midway Island
(GMT-10:00) Hawaii
(GMT-09:00) Alaska
(GMT-08:00) Pacific Time (US & Canada)
(GMT-08:00) Tijuana
(GMT-07:00) Arizona
(GMT-07:00) Chihuahua
(GMT-07:00) Mazatlan
(GMT-07:00) Mountain Time (US & Canada)
(GMT-06:00) Central America
(GMT-06:00) Central Time (US & Canada)
(GMT-06:00) Guadalajara
(GMT-06:00) Mexico City
(GMT-06:00) Monterrey
(GMT-06:00) Saskatchewan
(GMT-05:00) Bogota
(GMT-05:00) Eastern Time (US & Canada)
(GMT-05:00) Indiana (East)
(GMT-05:00) Lima
(GMT-05:00) Quito
(GMT-04:00) Atlantic Time (Canada)
(GMT-04:00) Caracas
(GMT-04:00) Georgetown
(GMT-04:00) La Paz
(GMT-04:00) Puerto Rico
(GMT-04:00) Santiago
(GMT-03:30) Newfoundland
(GMT-03:00) Brasilia
(GMT-03:00) Buenos Aires
(GMT-03:00) Greenland
(GMT-03:00) Montevideo
(GMT-02:00) Mid-Atlantic
(GMT-01:00) Azores
(GMT-01:00) Cape Verde Is.
(GMT+00:00) Casablanca
(GMT+00:00) Dublin
(GMT+00:00) Edinburgh
(GMT+00:00) Lisbon
(GMT+00:00) London
(GMT+00:00) Monrovia
(GMT+00:00) UTC
(GMT+01:00) Amsterdam
(GMT+01:00) Belgrade
(GMT+01:00) Berlin
(GMT+01:00) Bern
(GMT+01:00) Bratislava
(GMT+01:00) Brussels
(GMT+01:00) Budapest
(GMT+01:00) Copenhagen
(GMT+01:00) Ljubljana
(GMT+01:00) Madrid
(GMT+01:00) Paris
(GMT+01:00) Prague
(GMT+01:00) Rome
(GMT+01:00) Sarajevo
(GMT+01:00) Skopje
(GMT+01:00) Stockholm
(GMT+01:00) Vienna
(GMT+01:00) Warsaw
(GMT+01:00) West Central Africa
(GMT+01:00) Zagreb
(GMT+01:00) Zurich
(GMT+02:00) Athens
(GMT+02:00) Bucharest
(GMT+02:00) Cairo
(GMT+02:00) Harare
(GMT+02:00) Helsinki
(GMT+02:00) Jerusalem
(GMT+02:00) Kaliningrad
(GMT+02:00) Kyiv
(GMT+02:00) Pretoria
(GMT+02:00) Riga
(GMT+02:00) Sofia
(GMT+02:00) Tallinn
(GMT+02:00) Vilnius
(GMT+03:00) Baghdad
(GMT+03:00) Istanbul
(GMT+03:00) Kuwait
(GMT+03:00) Minsk
(GMT+03:00) Moscow
(GMT+03:00) Nairobi
(GMT+03:00) Riyadh
(GMT+03:00) St. Petersburg
(GMT+03:30) Tehran
(GMT+04:00) Abu Dhabi
(GMT+04:00) Baku
(GMT+04:00) Muscat
(GMT+04:00) Samara
(GMT+04:00) Tbilisi
(GMT+04:00) Volgograd
(GMT+04:00) Yerevan
(GMT+04:30) Kabul
(GMT+05:00) Ekaterinburg
(GMT+05:00) Islamabad
(GMT+05:00) Karachi
(GMT+05:00) Tashkent
(GMT+05:30) Chennai
(GMT+05:30) Kolkata
(GMT+05:30) Mumbai
(GMT+05:30) New Delhi
(GMT+05:30) Sri Jayawardenepura
(GMT+05:45) Kathmandu
(GMT+06:00) Almaty
(GMT+06:00) Astana
(GMT+06:00) Dhaka
(GMT+06:00) Urumqi
(GMT+06:30) Rangoon
(GMT+07:00) Bangkok
(GMT+07:00) Hanoi
(GMT+07:00) Jakarta
(GMT+07:00) Krasnoyarsk
(GMT+07:00) Novosibirsk
(GMT+08:00) Beijing
(GMT+08:00) Chongqing
(GMT+08:00) Hong Kong
(GMT+08:00) Irkutsk
(GMT+08:00) Kuala Lumpur
(GMT+08:00) Perth
(GMT+08:00) Singapore
(GMT+08:00) Taipei
(GMT+08:00) Ulaanbaatar
(GMT+09:00) Osaka
(GMT+09:00) Sapporo
(GMT+09:00) Seoul
(GMT+09:00) Tokyo
(GMT+09:00) Yakutsk
(GMT+09:30) Adelaide
(GMT+09:30) Darwin
(GMT+10:00) Brisbane
(GMT+10:00) Canberra
(GMT+10:00) Guam
(GMT+10:00) Hobart
(GMT+10:00) Melbourne
(GMT+10:00) Port Moresby
(GMT+10:00) Sydney
(GMT+10:00) Vladivostok
(GMT+11:00) Magadan
(GMT+11:00) New Caledonia
(GMT+11:00) Solomon Is.
(GMT+11:00) Srednekolymsk
(GMT+12:00) Auckland
(GMT+12:00) Fiji
(GMT+12:00) Kamchatka
(GMT+12:00) Marshall Is.
(GMT+12:00) Wellington
(GMT+12:45) Chatham Is.
(GMT+13:00) Nuku'alofa
(GMT+13:00) Samoa
(GMT+13:00) Tokelau Is.
symbols :
LLY
save search
Lilly to Acquire Sigilon Therapeutics
Published:
2023-06-29
(Crawled : 12:00)
- biospace.com/
SGTX
|
$22.47
-2.56%
0.0%
0
|
Health Technology
|
485.24%
|
O:
582.44%
H:
4.4%
C:
-21.14%
LLY
|
News
|
$750.77
0.54%
-0.04%
3.1M
|
Health Technology
|
62.79%
|
O:
0.08%
H:
1.47%
C:
1.18%
acquire
therapeutics
Lilly to Acquire POINT Biopharma to Expand Oncology Capabilities into Next-Generation Radioligand Therapies
Published:
2023-10-03
(Crawled : 12:00)
- biospace.com/
PNT
|
$13.68
2.63%
0.15%
0
|
|
88.33%
|
O:
85.39%
H:
0.81%
C:
0.41%
LLY
|
News
|
$750.77
0.54%
-0.04%
3.1M
|
Health Technology
|
39.3%
|
O:
0.19%
H:
0.0%
C:
0.0%
biopharma
acquire
Lilly to Acquire Akouos to Discover and Develop Treatments for Hearing Loss
Published:
2022-10-18
(Crawled : 11:00)
- prnewswire.com
PPRUF
|
News
|
$359.318
37.56%
490
|
Consumer Non-Durables
|
-22.29%
|
O:
2.47%
H:
0.06%
C:
-5.34%
PPRUY
|
News
|
$36.19
-0.11%
360K
|
Manufacturing
|
-20.2%
|
O:
2.62%
H:
0.0%
C:
-1.01%
LLY
|
News
|
$750.77
0.54%
-0.04%
3.1M
|
Health Technology
|
124.41%
|
O:
0.41%
H:
0.36%
C:
0.27%
AKUS
|
$13.29
1.07%
3.46%
|
Health Technology
|
74.55%
|
O:
73.76%
H:
1.83%
C:
0.61%
acquire
AC Immune Announces First Positive Cognitive Results for a Tau-Targeting Monoclonal Antibody in Alzheimer’s Disease
Published:
2021-08-31
(Crawled : 12:00)
- globenewswire.com
LLY
|
News
|
$750.77
0.54%
-0.04%
3.1M
|
Health Technology
|
184.68%
|
O:
0.2%
H:
0.3%
C:
-1.73%
ACIU
|
$2.45
0.0%
250K
|
Health Technology
|
-64.95%
|
O:
71.82%
H:
5.0%
C:
-32.31%
disease
alzheimer
positive
results
antibody
semorinemab
alzheimer’s
alzheimer's disease
alzheimer's
ALX Oncology Reports Positive Interim Phase 2 ASPEN-06 Clinical Trial Results of Evorpacept for the Treatment of Advanced HER2-Positive Gastric Cancer
Published:
2023-10-03
(Crawled : 10:00)
- globenewswire.com
LLY
|
News
|
$750.77
0.54%
-0.04%
3.1M
|
Health Technology
|
39.3%
|
O:
0.19%
H:
0.0%
C:
0.0%
ALXO
|
$16.08
10.97%
9.89%
2M
|
Commercial Services
|
201.25%
|
O:
68.19%
H:
2.84%
C:
-7.17%
aspen-06
positive
cancer
treatment
trial
results
ProQR Announces Conference Call to Discuss Axiomer® RNA Editing Platform
Published:
2022-12-22
(Crawled : 12:00)
- globenewswire.com
LLY
|
News
|
$750.77
0.54%
-0.04%
3.1M
|
Health Technology
|
102.91%
|
O:
-0.19%
H:
0.66%
C:
-0.55%
PRQR
|
$1.92
-4.0%
-4.17%
200K
|
Health Technology
|
21.21%
|
O:
64.85%
H:
13.97%
C:
-0.74%
axiomer
conference
platform
Lilly and ProQR to Expand RNA Editing Collaboration
Published:
2022-12-22
(Crawled : 12:00)
- prnewswire.com
LLY
|
News
|
$750.77
0.54%
-0.04%
3.1M
|
Health Technology
|
102.91%
|
O:
-0.19%
H:
0.66%
C:
-0.55%
PRQR
|
$1.92
-4.0%
-4.17%
200K
|
Health Technology
|
21.21%
|
O:
64.85%
H:
13.97%
C:
-0.74%
collaboration
Lilly and ProQR to Expand RNA Editing CollaborationNew agreement supports the discovery and development of additional assets directed toward high conviction targets utilizing ProQR’s Axiomer technology
Published:
2022-12-22
(Crawled : 13:00)
- biospace.com/
LLY
|
News
|
$750.77
0.54%
-0.04%
3.1M
|
Health Technology
|
102.91%
|
O:
-0.19%
H:
0.66%
C:
-0.55%
PRQR
|
$1.92
-4.0%
-4.17%
200K
|
Health Technology
|
21.21%
|
O:
64.85%
H:
13.97%
C:
-0.74%
axiomer
technology
agreement
Lilly and Foghorn Announce Strategic Collaboration for Novel Oncology Targets Using Foghorn’s Proprietary Gene Traffic Control® Platform
Published:
2021-12-13
(Crawled : 12:00)
- biospace.com/
LLY
|
News
|
$750.77
0.54%
-0.04%
3.1M
|
Health Technology
|
207.77%
|
O:
1.27%
H:
0.0%
C:
0.0%
FHTX
|
$5.76
-4.48%
-4.69%
130K
|
Health Technology
|
-49.5%
|
O:
51.84%
H:
0.0%
C:
0.0%
control
collaboration
platform
Veru’s Novel COVID-19 Drug Candidate Reduces Deaths by 55% in Hospitalized Patients in Interim Analysis of Phase 3 Study; Independent Data Monitoring Committee Halts Study Early for Overwhelming Efficacy
Published:
2022-04-11
(Crawled : 12:00)
- biospace.com/
LLY
|
News
|
$750.77
0.54%
-0.04%
3.1M
|
Health Technology
|
139.58%
|
O:
0.45%
H:
0.21%
C:
-1.32%
VERU
|
$1.165
-7.17%
-7.73%
2.5M
|
Health Technology
|
-71.15%
|
O:
37.7%
H:
143.24%
C:
105.01%
covid-19
drug
sabizabulin
phase 3
FDA States that Veru Should Submit Request for Emergency Use Authorization (EUA) Based on Positive Efficacy and Safety Data from the Phase 3 Clinical Study of Sabizabulin in Hospitalized COVID-19 Patients
Published:
2022-05-11
(Crawled : 11:00)
- biospace.com/
LLY
|
News
|
$750.77
0.54%
-0.04%
3.1M
|
Health Technology
|
155.8%
|
O:
-3.03%
H:
0.0%
C:
0.0%
VERU
|
$1.165
-7.17%
-7.73%
2.5M
|
Health Technology
|
-84.31%
|
O:
20.75%
H:
0.0%
C:
0.0%
covid-19
fda
sabizabulin
authorization
positive
phase 3
emergency use authorization
Enliven Therapeutics Appoints Dr. Lori Kunkel to Board of Directors
Published:
2024-04-09
(Crawled : 20:00)
- globenewswire.com
LLY
|
News
|
$750.77
0.54%
-0.04%
3.1M
|
Health Technology
|
-1.39%
|
O:
-0.71%
H:
0.0%
C:
0.0%
ORIC
|
$9.79
3.6%
3.47%
510K
|
Health Technology
|
-11.43%
|
O:
-2.81%
H:
1.54%
C:
-3.57%
NRIX
1 d
|
$14.1
-3.75%
-3.9%
970K
|
Health Technology
|
4.01%
|
O:
18.35%
H:
1.98%
C:
-5.88%
therapeutics
Lilly and Rigel Enter Strategic Collaboration to Develop RIPK1 Inhibitors for the Potential Treatment of Immunological and Neurodegenerative Diseases
Published:
2021-02-18
(Crawled : 12:11)
- prnewswire.com
LLY
|
News
|
$750.77
0.54%
-0.04%
3.1M
|
Health Technology
|
261.69%
|
O:
-0.56%
H:
0.06%
C:
-2.04%
RIGL
|
$1.115
-2.19%
-2.24%
580K
|
Health Technology
|
-74.83%
|
O:
17.44%
H:
3.38%
C:
-10.53%
disease
treatment
neurodegenerative
collaboration
potential
Positive Topline Data Shows Fostamatinib Meets Primary Endpoint of Safety in Phase 2 Clinical Trial in Hospitalized Patients with COVID-19
Published:
2021-04-13
(Crawled : 12:00)
- biospace.com/
LLY
|
News
|
$750.77
0.54%
-0.04%
3.1M
|
Health Technology
|
310.7%
|
O:
-0.35%
H:
1.36%
C:
0.75%
RIGL
|
$1.115
-2.19%
-2.24%
580K
|
Health Technology
|
-63.11%
|
O:
13.27%
H:
5.14%
C:
3.14%
covid
phase 2
positive
topline
trial
Lilly Plans to Invest Additional $450 million at Manufacturing Site in Research Triangle Park
Published:
2023-01-24
(Crawled : 12:00)
- prnewswire.com
LLY
|
News
|
$750.77
0.54%
-0.04%
3.1M
|
Health Technology
|
118.21%
|
O:
12.34%
H:
0.0%
C:
-9.9%
research
Veru Announces Presentation of Final Positive Phase 1b/2 Clinical Trial Results for Sabizabulin in Metastatic Castration Resistant Prostate Cancer at the 2022 American Society of Clinical Oncology Annual Meeting
Published:
2022-06-06
(Crawled : 11:00)
- globenewswire.com
LLY
|
News
|
$750.77
0.54%
-0.04%
3.1M
|
Health Technology
|
146.42%
|
O:
3.83%
H:
0.0%
C:
0.0%
VERU
|
$1.165
-7.17%
-7.73%
2.5M
|
Health Technology
|
-90.38%
|
O:
10.2%
H:
0.0%
C:
0.0%
sabizabulin
trial
presentation
positive
cancer
phase 2b
prostate cancer
AC Immune Provides Update on Alzheimer’s Disease Vaccine Candidates Targeting Pathological Amyloid-Beta
Published:
2021-06-02
(Crawled : 12:00)
- globenewswire.com
LLY
|
News
|
$750.77
0.54%
-0.04%
3.1M
|
Health Technology
|
276.34%
|
O:
0.3%
H:
0.96%
C:
0.06%
ACIU
|
$2.45
0.0%
250K
|
Health Technology
|
-61.54%
|
O:
9.89%
H:
2.4%
C:
-9.71%
disease
alzheimer
vaccine
aci-24
alzheimer’s
alzheimer's disease
alzheimer's
Veru Announces Date for FDA Advisory Committee Meeting to Review Emergency Use Authorization for Sabizabulin for Hospitalized COVID-19 Patients at High Risk for Acute Respiratory Distress Syndrome
Published:
2022-09-07
(Crawled : 18:00)
- globenewswire.com
LLY
|
News
|
$750.77
0.54%
-0.04%
3.1M
|
Health Technology
|
143.38%
|
O:
0.64%
H:
1.18%
C:
0.92%
VERU
|
$1.165
-7.17%
-7.73%
2.5M
|
Health Technology
|
-91.4%
|
O:
9.6%
H:
3.38%
C:
-28.02%
covid-19
fda
risk
sabizabulin
meeting
respiratory
review
authorization
Sangamo Therapeutics Announces Research Evaluation and Option Agreement With Prevail, a Wholly Owned Subsidiary of Lilly, for Novel Engineered Capsids
Published:
2023-07-17
(Crawled : 13:00)
- biospace.com/
LLY
|
News
|
$750.77
0.54%
-0.04%
3.1M
|
Health Technology
|
66.14%
|
O:
-0.0%
H:
0.26%
C:
-0.51%
SGMO
|
$0.513
-5.35%
-5.65%
1.2M
|
Health Technology
|
-57.98%
|
O:
9.3%
H:
0.71%
C:
-6.38%
wholly
research
therapeutics
agreement
AVEO Oncology Announces Clinical Trial Collaboration and Supply Agreement with Eli Lilly and Company for ERBITUX® (cetuximab) in North America to Evaluate Ficlatuzumab and Cetuximab in Patients with Recurrent or Metastatic HNSCC
Published:
2022-06-22
(Crawled : 12:00)
- investor.aveooncology.com
LLY
|
News
|
$750.77
0.54%
-0.04%
3.1M
|
Health Technology
|
154.86%
|
O:
1.31%
H:
0.0%
C:
0.0%
AVEO
|
$15.0
0.0%
0
|
Health Technology
|
230.29%
|
O:
8.59%
H:
9.93%
C:
5.88%
erbitux
america
collaboration
trial
agreement
← Previous
1
2
3
4
5
6
7
8
9
…
85
86
Next →
Gainers vs Losers
56%
44%
Top 10 Gainers
INVO
|
$1.76
131.58%
56.82%
230M
|
Health Technology
SINT
|
$0.0365
59.39%
37.26%
470M
|
Health Technology
WISA
4
|
$9.19
50.66%
33.7%
65M
|
Electronic Technology
EDBL
|
News
|
$6.73
47.91%
32.39%
13M
|
GCTK
|
$0.715
36.27%
26.62%
640K
|
Manufacturing
TCON
|
$2.33
36.26%
26.61%
2M
|
Health Technology
TIRX
|
$0.48
6.43%
24.58%
4.8M
|
KZIA
|
$0.38
30.58%
23.42%
300K
|
Health Technology
VNDA
|
News
|
$5.23
29.14%
22.56%
24M
|
Health Technology
ATNF
|
$1.91
29.05%
22.51%
310K
|
Your saved searches
Save your searches and get alerts when important news are released.